Guanglong Chen1, Ting Gong2, Zhe Wang3, Zeyu Wang4, Xiaolin Lin5, Sunrui Chen6, Chu Sun6, Weijie Zhao1, Ye Kong1, Huihan Ai1, Hang Yang1, Yusheng Liu6, Fangyan Wu6, Jiawei Kang7, Shasha Zhao8, Xiuying Xiao9, Jing Sun10, Aina He11, Zhi Li12. 1. Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, PRC, China. 2. Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin, China. 3. Department of Physiology, Second Military Medical University, Shanghai, China. 4. Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. 5. Department of Oncology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PRC, China. 6. Shanghai OneTar Biomedicine, Shanghai, China. 7. College of Fisheries and Life Science, Shanghai Ocean University, Shanghai, China. 8. State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, PRC, China. zhaoshasha@renji.com. 9. Department of Oncology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PRC, China. xiaoxiuying2002@163.com. 10. Department of General Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 200025, Shanghai, China. jingsun1982@sina.cn. 11. Department of Oncology, the Sixth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PRC, China. anna_1188@126.com. 12. Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, PRC, China. lizhipw316@163.com.
Abstract
PURPOSE: Oxaliplatin-based chemotherapy is a standard treatment for advanced colorectal cancer (CRC) patients. However, chemoresistance-induced resistance is an essential cause for mortality. Therefore, it is necessary to study the mechanism of drug resistance in CRC. METHODS: Here, we established two strains of patient-derived organoids (PDOs) selected from oxaliplatin-resistant and treatment-naïve CRC patients. To dissect the drug-resistant mechanisms, these CRC-PDOs were subjected to single-cell RNA sequencing (scRNA-Seq). RESULTS: We found that the drug sensitivity test outcome from these organoids subjected to oxaliplatin and 5-FU exposure was consistent with the clinic readout. CRC-PDOs well recapitulated the morphology and histology of their parental biopsies based on HE and IHC staining of pathological biomarkers. The scRNA-Seq data filtered drug-resistant cell populations and related signaling pathways (e.g. oxidative phosphorylation and ATP metabolic process). The data also revealed several putative drug resistant-driven genes (STMN1, VEGFA and NDRG1) and transcription factors (E2F1, BRCA1, MYBL2, CDX2 and CDX1). CONCLUSION: We generated an oxaliplatin-resistant CRC organoid model that was employed to provide potential therapeutic targets for treating CRC patients exhibiting oxaliplatin-resistance.
PURPOSE: Oxaliplatin-based chemotherapy is a standard treatment for advanced colorectal cancer (CRC) patients. However, chemoresistance-induced resistance is an essential cause for mortality. Therefore, it is necessary to study the mechanism of drug resistance in CRC. METHODS: Here, we established two strains of patient-derived organoids (PDOs) selected from oxaliplatin-resistant and treatment-naïve CRC patients. To dissect the drug-resistant mechanisms, these CRC-PDOs were subjected to single-cell RNA sequencing (scRNA-Seq). RESULTS: We found that the drug sensitivity test outcome from these organoids subjected to oxaliplatin and 5-FU exposure was consistent with the clinic readout. CRC-PDOs well recapitulated the morphology and histology of their parental biopsies based on HE and IHC staining of pathological biomarkers. The scRNA-Seq data filtered drug-resistant cell populations and related signaling pathways (e.g. oxidative phosphorylation and ATP metabolic process). The data also revealed several putative drug resistant-driven genes (STMN1, VEGFA and NDRG1) and transcription factors (E2F1, BRCA1, MYBL2, CDX2 and CDX1). CONCLUSION: We generated an oxaliplatin-resistant CRC organoid model that was employed to provide potential therapeutic targets for treating CRC patients exhibiting oxaliplatin-resistance.
Authors: Jose J G Marin; Fermin Sanchez de Medina; Beatriz Castaño; Luis Bujanda; Marta R Romero; Olga Martinez-Augustin; Rosario Del Moral-Avila; Oscar Briz Journal: Drug Metab Rev Date: 2012-05 Impact factor: 4.518
Authors: Rui Chen; George I Mias; Jennifer Li-Pook-Than; Lihua Jiang; Hugo Y K Lam; Rong Chen; Elana Miriami; Konrad J Karczewski; Manoj Hariharan; Frederick E Dewey; Yong Cheng; Michael J Clark; Hogune Im; Lukas Habegger; Suganthi Balasubramanian; Maeve O'Huallachain; Joel T Dudley; Sara Hillenmeyer; Rajini Haraksingh; Donald Sharon; Ghia Euskirchen; Phil Lacroute; Keith Bettinger; Alan P Boyle; Maya Kasowski; Fabian Grubert; Scott Seki; Marco Garcia; Michelle Whirl-Carrillo; Mercedes Gallardo; Maria A Blasco; Peter L Greenberg; Phyllis Snyder; Teri E Klein; Russ B Altman; Atul J Butte; Euan A Ashley; Mark Gerstein; Kari C Nadeau; Hua Tang; Michael Snyder Journal: Cell Date: 2012-03-16 Impact factor: 41.582
Authors: Marine Fidelle; Satoru Yonekura; Marion Picard; Alexandria Cogdill; Antoine Hollebecque; Maria Paula Roberti; Laurence Zitvogel Journal: Front Immunol Date: 2020-12-14 Impact factor: 7.561